Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Biofocussed Prostate Cancer RadioTherapy (BiRT): A Personalised Approach To Delivering The Right Dose To The Right Place
Funder
National Health and Medical Research Council
Funding Amount
$753,565.00
Summary
We propose a new approach to treating prostate cancer with radiotherapy to move from the standard whole prostate treatment to a personalised treatment that varies radiation intensity throughout the prostate. We will mathematically combine features that influence radiotherapy effect from advanced imaging, clinical and biopsy information. This model will map out the radiotherapy dose required at each part of the prostate, to maximise killing of the cancer whilst minimising harm to normal tissue
Assessment Of Rectal And Urinary Toxicity From The RADAR Prostate Radiotherapy Trial – Dosimetric Constraints For Novel Symptom Clustering, Derivation Of Radiobiological Parameters And Assessment Of Patient Localisation Effects
Funder
National Health and Medical Research Council
Funding Amount
$323,484.00
Summary
Increasing prostate radiotherapy cure rates by increasing radiation dose is limited by side-effects in the rectum and bladder which can greatly decrease patient quality of life. This study will utilise detailed data, collected during a large Australasian trial, to extract information on how patterns of dose delivery influence side-effects in the bladder and rectum, including a novel definition of rectal toxicity. The result will be more effective future treatment.
Quality Assurance In LDR And HDR Prostate Brachytherapy
Funder
National Health and Medical Research Council
Funding Amount
$221,500.00
Summary
Prostate cancer is one of the most commonly diagnosed cancers in men over 55 years of age. Approximately 30% of all diagnosed cancers in this age group are prostate carcinomas. Low and high dose rate brachytherapy are newly established treatment options for early-stage, low-risk, prostate cancer and are an alternative to curative prostatectomy in most patients. Local control and cure of prostate cancer is greatly influenced by the dose distribution generated by both the treatment techniques. Tre ....Prostate cancer is one of the most commonly diagnosed cancers in men over 55 years of age. Approximately 30% of all diagnosed cancers in this age group are prostate carcinomas. Low and high dose rate brachytherapy are newly established treatment options for early-stage, low-risk, prostate cancer and are an alternative to curative prostatectomy in most patients. Local control and cure of prostate cancer is greatly influenced by the dose distribution generated by both the treatment techniques. Treatment plans must be able to deliver a prescribed dose in the tumour, with adequate margins, while minimising the dose delivered to the surrounding normal tissue and critical organs. It is well recognised that, however skilful the radiation oncologist, an ideal dose distribution according to a treatment plan plan does not guarantee a well delivered dose. Complications such as impotence, severe radiation urethritis and severe rectal bleeding will arise if overdosing of the neuro-vascular bundle, urethra and rectum occurs respectively. This project is based on newly developed instrumentation that will allow continuous, realtime, in vivo, monitoring of the radiation dose levels in the urethra and rectum during brachytherapy treatment of prostate cancer. Such monitoring of the treatment procedure, has been identified as a high priority by the American Brachytherapy Society. The technique will allow extensive in vivo and post treatment studies to be performed by clinicians so as to measure the dose levels currently received and identify the optimum acceptable dose levels for future procedures. The outcomes of this project may well be able to be utilised in other forms of brachytherapy treament (e.g. breast, cervical cancer) and other radiation treatment modailities (e.g. conventional radiotherapy and intensity modulated radiotherapy) to also reduce complications associated with these treatment modalities.Read moreRead less